Merck Secures 30th Approval for KEYTRUDA in Europe
Merck, known as MSD outside of the United States and Canada, proudly announces that the European Commission has granted two new approvals for its groundbreaking medication, KEYTRUDA (pembrolizumab). This innovative anti-PD-1 therapy now has additional indications in the treatment of gynecologic cancers, specifically in tackling aggressive forms of endometrial and cervical cancers.
Understanding the Latest Approvals
The first new indication allows for the combined use of KEYTRUDA with carboplatin and paclitaxel to address primary advanced or recurrent endometrial carcinoma as the first-line therapy for adult patients eligible for systemic treatment. The second indication allows KEYTRUDA, used in combination with chemoradiotherapy, to treat patients suffering from FIGO 2014 Stage III-IVA locally advanced cervical cancer who have not undergone previous definitive treatment. This significant progress means KEYTRUDA has now achieved a remarkable total of 30 approvals within the European Union for various types of cancers.
Impact on Treatment Paradigms
Dr. Gursel Aktan, Merck's Vice President of Global Clinical Development, emphasizes the importance of these approvals, stating, "These KEYTRUDA-based regimens have the potential to change the treatment landscape for individuals facing endometrial and cervical cancer, which are among the most common cancers affecting women in Europe." This reinforces Merck’s commitment to providing innovative solutions that can adapt to the needs of diverse patient groups.
Clinical Trials Behind the Approvals
The approvals are grounded in robust clinical evidence drawn from the Phase 3 NRG-GY018 trial (KEYNOTE-868) and the Phase 3 KEYNOTE-A18 trial (ENGOT-cx11/GOG-3047). Both studies have shown positive outcomes, with KEYTRUDA combinations demonstrating statistically significant improvements in progression-free survival rates compared to traditional treatments.
Wider Availability of KEYTRUDA
With these new indications, KEYTRUDA will be available across all 27 EU member states, as well as in Iceland, Liechtenstein, Norway, and Northern Ireland. The exact timelines for making KEYTRUDA accessible in specific countries will vary, largely due to the completion of national reimbursement processes which can affect the speed at which these treatments are integrated into healthcare systems.
Previous U.S. Approvals and Future Prospects
Prior to these EU announcements, the U.S. had granted FDA approval for KEYTRUDA in similar treatment settings for endometrial and cervical cancers, showcasing its efficacy in reducing disease progression significantly. As clinical research continues to evolve, Merck remains focused on identifying additional therapeutic applications for KEYTRUDA.
About Endometrial and Cervical Cancers
Endometrial carcinoma originates in the uterus's inner lining and ranks as the most prevalent uterine cancer globally. Notably, there were approximately 420,368 diagnoses of endometrial cancer worldwide in a recent year, including significant mortality rates. Cervical cancer, on the other hand, primarily affects the lower part of the uterus and continues to be a leading health concern for women worldwide, contributing to high incidence and mortality figures despite advancements in preventive measures.
Merck's Commitment to Women's Health
Through its ongoing research initiatives, Merck is dedicated to enhancing treatment options aimed at improving patient outcomes in various forms of women's cancers, including breast, ovarian, and cervical cancers. With over 20 clinical trials encompassing more than 18,000 participants globally, Merck underscores its commitment to transforming the landscape of women's health and providing hope to those affected.
Frequently Asked Questions
What is KEYTRUDA?
KEYTRUDA is an immune-therapy drug that helps the body’s immune system recognize and fight cancer cells more effectively.
Which new indications were approved for KEYTRUDA?
KEYTRUDA received approvals for the treatment of primary advanced or recurrent endometrial carcinoma and FIGO Stage III-IVA cervical cancer.
Where is KEYTRUDA available following these approvals?
After the latest approvals, KEYTRUDA is now available in all EU member states and certain associated regions.
What were the reasons behind the EC approvals for KEYTRUDA?
The approvals were based on positive outcomes from two Phase 3 clinical trials demonstrating significant improvements in patient survival rates.
How does Merck plan to support access to KEYTRUDA?
Merck is committed to working with healthcare systems to facilitate the timely availability of KEYTRUDA across the approved regions, navigating through necessary reimbursement processes.
